newsfilter
← Latest News
PR Newswire·

Innovative Immunology Biotech Windward Bio Lists on Nasdaq

  • Windward Bio successfully listed on Nasdaq on November 13, 2026, with an IPO price of $17.00 per share.
  • Shares closed at $28.50 on the first trading day, representing a 68% increase & a market capitalization of approximately $1.69 billion.
  • Qiming Venture Partners invested in Windward Bio's Series A financing in 2025, supported the Series B in 2026, & participated in the IPO round.
  • This event marks Qiming Venture Partners' 11th IPO in 2026.
  • Founded in 2024, Windward Bio aims to treat chronic inflammatory diseases using ultra-long-acting antibody medicines for conditions like asthma, COPD, & atopic dermatitis.
  • The lead program WIN378 is a long-acting anti-TSLP monoclonal antibody currently under evaluation in the POLARIS-1 (Phase 2/3) & SIRIUS (Phase 2) studies.
  • The pipeline includes WIN027, a clinical-stage bispecific antibody targeting TSLP & IL-13, licensed from Qyuns Therapeutics.
  • Windward Bio holds exclusive global rights to WIN378 (excluding Greater China & certain Asian countries) through agreements with Kelun-Biotech & Harbour BioMed.
  • Qiming Venture Partners manages $9.5 billion in capital across 18 funds & has supported over 290 portfolio company exits since its 2006 founding.
Company
Qiming Venture Partners
Keywords
Qiming Venture Partners